Until now, an affordable option with high accuracy and high diagnostic yields has been lacking. Fortunately, Body Vision’s lung navigation and biopsy guidance platform LUNGVISION™ offers a unique opportunity for our community with the promise to improve patient outcome AND increase cost efficiencies to the hospital.
One of the main questions we asked ourselves when setting out to develop the LUNGVISION™ Platform is this: How can we help make early stage lung cancer diagnostics and treatment accessible to more physicians, hospitals, and, ultimately, patients? We decided to challenge ourselves to both significantly improve clinical outcomes, while also lowering the cost of these types of procedures.
We believe that behind a great product design there are three main components: cutting edge technology, ability to constantly listen to physician’s feedback, and a product mindset.
Our philosophy is to focus on the key user needs; therefore, we constantly gain knowledge from user feedback in order to improve our product. We treat our physicians as our partners, proactively detecting pains and gaps while providing creative solutions to their problems.
Each hospital has different needs and requirements; we tailor our education strategy to make sure that they have what they need to be successful on day one. We have built this in-depth program with the aim to raise the standards for a hospital’s preparedness to begin navigation bronchoscopy using the LungVision Platform.
The LungVision Platform is a disruptive technology, unlike any other navigation platform on the market today, providing biopsy guidance in real time by means of artificial intelligence.
At Body Vision, we invest a superior effort in human resources and team-building activities. Our culture inspires challenges and achievements; however, the ways to achieve our goals and our communication habits are equally important.
The ability to detect and diagnose lung cancer at an early stage leads to a cure in the majority of patients. Companies, including Body Vision Medical, are taking great strides towards making early stage, minimally invasive lung cancer diagnostics accessible to more hospitals, physicians, and ultimately, patients throughout the world.
Local minimally invasive therapies in the lung are the only option for non-surgical patients. Moreover, these therapies provide a legitimate alternative for the larger patient population due to reduced associated risks, lower costs and timely availability in procedure room. Ongoing studies suggest that if applied at the accurate location of the lesion, some local therapies may increase the patient survival rate. However, until today, it has been challenging to apply local therapies to small pulmonary nodules in a standard bronchoscopy suite since the nodules are invisible through conventional imaging modalities and are very tricky to reach. The LungVision™ platform is opening a new era in local therapies since it makes any nodule visible and accessible in real time, while tracking tissue movement during breathing and instrument placement.
According to the American Cancer Society, three out of four American families will have a family member diagnosed with some form of cancer. That’s a lot of people who need love and support from the people closest to them, lots of opportunities to make a positive impact for people who find themselves fighting the biggest challenge of their lives.
Shape matching, stereo reconstruction, motion estimation, image restoration, and object segmentation are all problems in the field of Computer Vision that are often solved using global optimization methods. In this post, we will present typical nonlinear optimization challenges and suggest a graceful solution.